Proactive Investors - Run By Investors For Investors

AusCann Group acquires R&D facility to develop cannabinoid product pipeline

The facility will support the development of existing and new cannabinoid formulations.
AusCann Group acquires R&D facility to develop cannabinoid product pipeline
AusCann holds the full set of necessary licences to grow and manufacture cannabinoid medicines in Australia

AusCann Group Holdings Ltd (ASX:AC8) has acquired a 7,300 square metre research and development (R&D) facility in Perth, Western Australia.

The facility will focus on AusCann’s cannabinoid pharmaceutical product pipeline, supporting development of innovative formulations and dose forms.

READ: AusCann Group DayaCann joint venture to commence crop cultivation with Khiron

AusCann executive director & interim CEO Paul MacLeman said the acquisition of the R&D site was a major stepping stone for the company.

He said: “It allows the creation of a fully-integrated, state-of-the-art facility for medicinal cannabis.”

The facility was purchased for $5.25 million and AusCann will invest up to $6 million over time to customise and fit out the site for use during 2019.

The acquisition and upgrade costs will be funded from AusCann’s cash balance which was more than $40 million prior to the acquisition.

READ: AusCann Group shortlists candidates for chief executive officer role

MacLeman added: “AusCann’s key point of difference compared to other cannabis producers is our commitment to a rigorous pharmaceutical development program.

“[This] will now be strengthened through the establishment of our own facility to support further R&D towards bringing new products to market.

“2019 will be a major year for AusCann with the planned launch of our hard-shell cannabinoid capsules which addresses the need for stability and consistency of dose.

“Our partner PCI Pharma is manufacturing the first product line as we aim to commence the production of our capsules towards the middle of this year.”

READ: AusCann Group appoints PCI Pharma to manufacture first product line

The cannabinoid capsules are expected to be released this year and are for the treatment of chronic pain.

They will initially target a market that is estimated to be 1.9 million Australians who suffer chronic neuropathic pain.

Sufferers can access the treatment through the Therapeutic Goods Administration’s (TGA) special access scheme.

Around 3.2 million Australians suffer chronic pain and existing treatments are lacking in efficacy and have notable side effects.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

cannabis tablet
February 28 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products
May 07 2019
TGOD has been busy building out its facilities in Ontario, Quebec, and Jamaica and expects to reach combined production of 219,000 kilograms of cannabis around 2021
Empower clinic locations
March 26 2019
Empower Clinics is one of the largest operators of medical-cannabis-focused healthcare in the US
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use